Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion, increasing blood sugar disposal, and improving glycemic control
Not the drug people are searching for The one trial in an adjacent indication Crohn's disease, 2010 produced remission rates its own authors called only numerically higher than placebo, and no successful phase 3 followed in sixteen years
Research progress Support The animal experiments have achieved remarkable results: In the obese mouse model, after daily subcutaneous injection of AOD 9604 (250 g/kg) for 8 weeks, the body weight of the mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue significantly decreased, confirming its effectiveness in fat reduction
A common research-planning SubQ start is 50 mg (about 0.50 mL at 100 mg/mL) once weekly or three times weekly, then escalate by ~25 mg as tolerated
While their effectiveness is well-documented, understanding their safety is paramount
Honest mistakes that can unfortunately derail important research